For research use only. Not for therapeutic Use.
Tr-PEG2-OH(CAT: I016671) stands as an essential component within the realm of PROTAC-based drug design. This PEG-based linker plays a pivotal role in facilitating the construction of PROTAC molecules. By serving as a bridge between the ligand targeting the protein of interest and the ligand for E3 ubiquitin ligase, Tr-PEG2-OH enables the assembly of PROTACs, which are engineered to induce targeted protein degradation.
| Catalog Number | I016671 |
| CAS Number | 105589-77-3 |
| Molecular Formula | C₂₃H₂₄O₃ |
| Purity | ≥95% |
| Target | Antibody-drug Conjugate/ADC Related |
| Reference | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.<br>[2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. |
